Why Novavax Stock Is Sinking Again Today

What happened

Shares of Novavax (NASDAQ: NVAX) were sinking 9% lower as of 11:23 a.m. EDT on Tuesday after dropping nearly 14% on Monday. The reason behind today's decline appears to be the same as it was yesterday: Investors are concerned that another COVID-19 vaccine could receive emergency use authorization (EUA) in October. A Financial Times article published on Sunday reported that the Trump administration was considering fast-tracking the COVID-19 vaccine being developed by AstraZeneca and the University of Oxford. 

So what

On one hand, it doesn't make sense why investors would sell off Novavax shares on worries about another COVID-19 vaccine making it to market sooner. After all, Novavax only started a phase 2 clinical study of its coronavirus vaccine candidate NVX-CoV2373 yesterday. Several drugmakers are already in phase 3 testing with their COVID-19 vaccine candidates. No one expected Novavax to be the first to market with its vaccine.

Gloved hand picking a COVID-19 vaccine bottle from a line of similar bottles

Image source: Getty Images.

However, Novavax's market cap of around $6.6 billion is still pretty steep considering the company doesn't have any approved product on the market yet. Any news that could be construed as bad in any way for its prospects is likely to cause the biotech stock to fall. That's what we've seen happen this week.

These downswings are merely noise, though. The important thing to watch with Novavax is how NVX-CoV2373 performs in phase 2 testing.

Now what

Novavax plans to enroll up to 1,500 healthy volunteers in its phase 2 study at as many as 40 sites in the U.S. and Australia. Roughly half of those participants will be ages 60 and older. That's important since older individuals are at greater risk with COVID-19. The company expects to report interim data from this study in the fourth quarter of 2020. 

10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More